Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Q Biotechnologies Ltd
Street 1: S12 Sparkhouse Building, University of Lincoln
Street 2: Ropewalk
City: Lincoln
Province: Lincolnshire
Post Code: LN6 7DQ
Country: United Kingdom of Great Britain and Northern Ireland
Phone: 01522 837220
Organization Email:
Web Site:
Other Online Presence:

Focal Point Contact Information

Salutation: Miss
First Name: Claire
Last Name: Bryan
Title: Communications Officer
Phone: 01522837220

Alternate Focal Point Contact Information

Salutation: Dr
First Name: Andrew
Last Name: Kemp
Title: Principle Scientific Officer

General Information

Board Constituency: Private sector
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Private Sector
Organization Type - Secondary: Company
Organization Description:
Q Biotechnologies Ltd is a progressive organisation that develops, manufactures and distributes under exclusive license, products for disease prevention. Our portfolio includes rapid and accurate testing, persistent surface and skin disinfectants and capital equipment.
We are interested in TB because we have international distributors of our persistent SiQuat Q Shield. This has been used in South Africa to prevent TB/HIV and fungal infections in mine workers. We intend to conduct further research in country on early diagnosis to prevent the spread of infection. We would like to get involved with national and international projects for prevention, early detection and sharing best practice. Our SiQuat is currently being used in hospital studies to prevent SSIs, we actively share this data to encourage a new emphasis on prevention rather than cure. Dr Kemp is involved with leading microbiologists in the NHS, to write a new environmental cleaning directive which we would hope can be incorporated into every setting to reduce infection rates.
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Provision of drugs, diagnostics and commodities
Research and Development
Technical Assistance

Other Organization Information

Total number of staff in your organization: 1 - 5
Number of full-time staff who are directly involved with TB: 1 - 5
Number of part-time staff who are directly involved with TB: 0
Number of volunteers who are directly involved with TB: 0
How did you hear about the Stop TB Partnership: Media
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Involvement in Stop TB Working Groups
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: No
Please tell us how your organization is contributing to your country's national TB control plan:
We do not currently contribute to the national control plan, we are actively looking for opportunities to do this.

Geographical Reach

Which country is your headquarters located in: United Kingdom of Great Britain and Northern Ireland
Which countries do you do operate in:
(This includes countries you are conducting activities in)
South Africa
United Kingdom of Great Britain and Northern Ireland
United States of America


Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

We will run further testing on TB with a view to campaign for the use of persistent products to prevent infection. Raising awareness and sharing best practice in surface disinfection and decontamination is our goal to prevent people from getting TB.

New Diagnostics:
Our portfolio includes rapid and accurate testing.

We will be actively looking for opportunities to research effectiveness of using persistent products over non persistent to prevent infection.


Declaration of interests:
No conflicts of interest were delacred.

Application date: November 22, 2017
Last updated: November 29, 2017